Skip to main content
Clinical Trials/NCT03865654
NCT03865654
Completed
Not Applicable

Individualizing Surveillance Mammography for Older Breast Cancer Survivors

Dana-Farber Cancer Institute1 site in 1 country45 target enrollmentMay 16, 2019
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Dana-Farber Cancer Institute
Enrollment
45
Locations
1
Primary Endpoint
Rate of Change in Intentions for Mammography in the Next Year
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This research is being conducted to develop consensus on surveillance mammography and follow-up for breast cancer survivors who are age ≥75.

Detailed Description

The investigators will develop a communication tool that summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors age ≥75. Developing expert-panel recommendations, examining clinician and patient attitudes towards these recommendations, and testing a strategy for communication of expert recommendations on mammography cessation through direct engagement of specialists, primary care clinicians (PCs), and patients. This is a multi-step study, the investigators will build on prior steps to develop consensus on surveillance mammography and follow-ups for breast cancer survivors who are age \>= 75. This study includes a physician focus group.

Registry
clinicaltrials.gov
Start Date
May 16, 2019
End Date
July 1, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rachel Freedman, MD, MPH

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • Female gender, given that screening guidelines do not exist for men
  • Receiving part or all of their care at DFCI
  • Ages 75-79 (approximately 15 patients)
  • Age ≥80 (approximately 15 patients)
  • History of stage 0-II breast cancer
  • ≥1 Charlson comorbidity present72, defined as one of the following:
  • Liver disease
  • History of or other active malignancy other than non-melanoma skin cancers
  • HIV or AIDS
  • Chronic kidney disease

Exclusion Criteria

  • Are unable to consent
  • Who do not read and write English (for this initial pilot)

Outcomes

Primary Outcomes

Rate of Change in Intentions for Mammography in the Next Year

Time Frame: 2 years

Survey measure on whether mammography will be done or not

Secondary Outcomes

  • Rate of Satisfaction(2 years)
  • Preferred Decision-making Role(2 years)

Study Sites (1)

Loading locations...

Similar Trials